Home
Search
Search Results
Previously Searched
3114 results found
Expand All
Apply All
3114 results found

BIO Partnering @JPM Week (Day 2)
January 9, 2024
Registration and the BIO One-on-One Partnering™ System are now open! BIO One-on-One Partnering unifies access to partnering for the life science industry. You can efficiently arrange meetings with biotechs, investors, in-licensors, medical device and medtech companies, and other life science leaders, regardless of whether you are registered for a specific event during JPM Week.
Read More

Small fix to IRA, big boost for rare disease
Good Day BIO Newsletter  •  January 9, 2024
A small fix to the Inflation Reduction Act could boost rare disease R&D—and voters support it. Plus, researchers say they found the gene that allows wheat to grow in extreme temperatures. (487 words, 2 minutes, 26 seconds)
Read More

BIO Comments to HHS on their proposed Notice of Benefit and Payment Parameters (NBPP) for 2025
Letters, Testimony & Comments  •  January 8, 2024
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Department of Health and Human Services’ (HHS’) proposed Notice of Benefit and Payment Parameters (NBPP) for 2025.
Read More

BIO Partnering @JPM Week (Day 1)
January 8, 2024
Registration and the BIO One-on-One Partnering™ System are now open! BIO One-on-One Partnering unifies access to partnering for the life science industry. You can efficiently arrange meetings with biotechs, investors, in-licensors, medical device and medtech companies, and other life science leaders, regardless of whether you are registered for a specific event during JPM Week.
Read More

JPM Week begins
Good Day BIO Newsletter  •  January 8, 2024
JPM Week begins, Congress is back to work, and the likelihood of the next pandemic looms. (501 words, 2 minutes, 30 seconds)
Read More

How IP enables innovation
Good Day BIO Newsletter  •  January 5, 2024
Writing in The Hill, BIO’s Chief Policy Officer John Murphy explains how IP enables innovation and access to COVID technology. Meanwhile, BIO has joined an amicus brief against a lawsuit that questions a drug company’s decisions about the pace of drug development. (481 words, 2 minutes, 24 seconds)
Read More

The SDGs require biotech
Good Day BIO Newsletter  •  January 4, 2024
BIO helps report on biotech’s contributions to global sustainability. One such contribution is the effort to battle a surge in dengue. (496 words, 2 minutes, 28 seconds)
Read More

EPA greenlights groundbreaking biopesticide
Good Day BIO Newsletter  •  January 3, 2024
The EPA greenlit a BIO member’s groundbreaking biopesticide that targets a “super pest”—without harming the honeybees. Plus, we look at how Genentech’s MS clinical trial brings lessons on MS and clinical trial diversity. (538 words, 2 minutes, 41 seconds)
Read More

19 Congressional Democrats send letter to USTR on Trips Waiver
Letters, Testimony & Comments  •  January 2, 2024

What you missed on IP, SAF tax credits, drug prices
Good Day BIO Newsletter  •  January 2, 2024
Happy 2024! Today, we have news you might have missed over the holidays: 19 House Democrats oppose expanding the COVID IP waiver, the IRS issues new guidance on SAF tax credits, and BIO talks PBMs and drug prices. (557 words, 2 minutes, 47 seconds)
Read More